Enfusion, Inc. (NYSE:ENFN) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in Enfusion, Inc. (NYSE:ENFN - Free Report) by 17.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,487,815 shares of the company's stock after acquiring an additional 512,479 shares during the quarter. Vanguard Group Inc. owned about 2.74% of Enfusion worth $31,286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of ENFN. Lazard Asset Management LLC bought a new position in shares of Enfusion in the 4th quarter worth about $28,000. Amalgamated Bank grew its position in Enfusion by 33.7% during the 3rd quarter. Amalgamated Bank now owns 5,230 shares of the company's stock valued at $47,000 after purchasing an additional 1,317 shares during the last quarter. UBS Group AG grew its position in Enfusion by 1,189.8% during the 4th quarter. UBS Group AG now owns 6,204 shares of the company's stock valued at $60,000 after purchasing an additional 5,723 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Enfusion by 783.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,598 shares of the company's stock valued at $68,000 after purchasing an additional 6,738 shares during the last quarter. Finally, Barclays PLC grew its position in Enfusion by 494.6% during the 4th quarter. Barclays PLC now owns 7,248 shares of the company's stock valued at $70,000 after purchasing an additional 6,029 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ENFN has been the topic of several recent analyst reports. The Goldman Sachs Group downgraded shares of Enfusion from a "neutral" rating to a "sell" rating and cut their price objective for the company from $9.00 to $8.00 in a research report on Wednesday, February 28th. Bank of America raised their price target on shares of Enfusion from $8.00 to $9.00 and gave the company an "underperform" rating in a report on Wednesday, March 13th. JPMorgan Chase & Co. downgraded shares of Enfusion from a "neutral" rating to an "underweight" rating and dropped their price target for the company from $11.00 to $9.00 in a report on Tuesday, January 30th. Finally, Piper Sandler raised their price target on shares of Enfusion from $9.00 to $10.00 and gave the company a "neutral" rating in a report on Wednesday, December 20th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $9.33.

Enfusion Price Performance

Shares of NYSE:ENFN traded up $0.04 during trading on Friday, hitting $9.57. The company's stock had a trading volume of 269,388 shares, compared to its average volume of 394,369. Enfusion, Inc. has a 12 month low of $7.37 and a 12 month high of $11.56. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of 119.64, a P/E/G ratio of 2.79 and a beta of 1.00. The company has a 50-day moving average of $8.98 and a 200-day moving average of $9.10.

Enfusion (NYSE:ENFN - Get Free Report) last released its earnings results on Tuesday, March 12th. The company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). Enfusion had a return on equity of 10.30% and a net margin of 3.45%. The firm had revenue of $46.49 million for the quarter, compared to the consensus estimate of $45.56 million. As a group, research analysts anticipate that Enfusion, Inc. will post 0.07 earnings per share for the current year.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.